Momenta Pharmaceuticals, Inc. (MNTA)

[GrthzGd]

At its Annual Meeting last month, CW said they were compiling and would soon present at an upcoming conference a thorough strategic review to refocus MNTA's business on its new drug candidates. On June 29th, hey filed an 8-K pushing the update back a month or so:

In January 2018, Momenta announced the initiation of a strategic review of its business including, but not limited to, evaluating options for new partnerships across the Company’s portfolio, additional cost reduction strategies, and the sale of certain assets such as M923. The Company subsequently set a goal to complete the review by the end of the second quarter of 2018. At this time, the strategic review is progressing, but is not yet complete and the Company plans to provide an update on the strategic review either before, or at the same time as, the Company reports its second quarter 2018 financial
results.